vs
Side-by-side financial comparison of American Express (AXP) and ZEVRA THERAPEUTICS, INC. (ZVRA). Click either name above to swap in a different company.
ZEVRA THERAPEUTICS, INC. is the larger business by last-quarter revenue ($34.1M vs $18.9M, roughly 1.8× American Express). On growth, ZEVRA THERAPEUTICS, INC. posted the faster year-over-year revenue change (183.4% vs 11.4%). Over the past eight quarters, ZEVRA THERAPEUTICS, INC.'s revenue compounded faster (215.7% CAGR vs -95.6%).
American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...
Zevra Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with rare under-treated orphan diseases, with a primary focus on central nervous system and metabolic rare disorder segments. Its main target markets are North America and the European Union.
AXP vs ZVRA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.9M | $34.1M |
| Net Profit | $3.0M | — |
| Gross Margin | — | — |
| Operating Margin | — | 27.3% |
| Net Margin | 15.7% | — |
| Revenue YoY | 11.4% | 183.4% |
| Net Profit YoY | 15.0% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $18.9M | — | ||
| Q4 25 | $10.9B | $34.1M | ||
| Q3 25 | $10.4B | $26.1M | ||
| Q2 25 | $10.3B | $25.9M | ||
| Q1 25 | $9.6B | $20.4M | ||
| Q4 24 | $10.0B | $12.0M | ||
| Q3 24 | $9.7B | $3.7M | ||
| Q2 24 | $9.8B | $4.4M |
| Q1 26 | $3.0M | — | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.9B | $-544.0K | ||
| Q2 25 | $2.9B | $74.7M | ||
| Q1 25 | $2.6B | $-3.1M | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.5B | $-33.2M | ||
| Q2 24 | $3.0B | $-19.9M |
| Q1 26 | — | — | ||
| Q4 25 | 28.2% | 27.3% | ||
| Q3 25 | 36.7% | 15.9% | ||
| Q2 25 | 34.4% | -274.5% | ||
| Q1 25 | 34.6% | -26.3% | ||
| Q4 24 | 27.7% | -128.0% | ||
| Q3 24 | 33.0% | -739.0% | ||
| Q2 24 | 38.6% | -534.8% |
| Q1 26 | 15.7% | — | ||
| Q4 25 | 22.5% | — | ||
| Q3 25 | 27.9% | -2.1% | ||
| Q2 25 | 28.0% | 288.7% | ||
| Q1 25 | 26.8% | -15.2% | ||
| Q4 24 | 21.8% | — | ||
| Q3 24 | 25.8% | -899.2% | ||
| Q2 24 | 30.7% | -447.9% |
| Q1 26 | — | — | ||
| Q4 25 | $3.52 | — | ||
| Q3 25 | $4.14 | $-0.01 | ||
| Q2 25 | $4.08 | $1.21 | ||
| Q1 25 | $3.64 | — | ||
| Q4 24 | $3.04 | — | ||
| Q3 24 | $3.49 | $-0.69 | ||
| Q2 24 | $4.15 | $-0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $62.4M |
| Total DebtLower is stronger | $60.4M | $61.9M |
| Stockholders' EquityBook value | $34.0M | $154.7M |
| Total Assets | $308.9M | $284.7M |
| Debt / EquityLower = less leverage | 1.78× | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $742.0M | $62.4M | ||
| Q3 25 | $1.3B | $54.4M | ||
| Q2 25 | $197.0M | $47.7M | ||
| Q1 25 | $261.0M | $37.3M | ||
| Q4 24 | $221.0M | $33.8M | ||
| Q3 24 | $120.0M | $54.0M | ||
| Q2 24 | $188.0M | $39.3M |
| Q1 26 | $60.4M | — | ||
| Q4 25 | $56.4B | $61.9M | ||
| Q3 25 | $57.8B | $61.3M | ||
| Q2 25 | $58.2B | $60.7M | ||
| Q1 25 | $51.2B | — | ||
| Q4 24 | $49.7B | $59.5M | ||
| Q3 24 | $53.5B | — | ||
| Q2 24 | $51.5B | — |
| Q1 26 | $34.0M | — | ||
| Q4 25 | $33.5B | $154.7M | ||
| Q3 25 | $32.4B | $133.2M | ||
| Q2 25 | $32.3B | $117.2M | ||
| Q1 25 | $31.2B | $41.0M | ||
| Q4 24 | $30.3B | $39.7M | ||
| Q3 24 | $29.7B | $69.8M | ||
| Q2 24 | $29.5B | $32.5M |
| Q1 26 | $308.9M | — | ||
| Q4 25 | $300.1B | $284.7M | ||
| Q3 25 | $297.6B | $270.1M | ||
| Q2 25 | $295.6B | $256.3M | ||
| Q1 25 | $282.2B | $172.7M | ||
| Q4 24 | $271.5B | $178.1M | ||
| Q3 24 | $271.0B | $191.6M | ||
| Q2 24 | $272.2B | $144.4M |
| Q1 26 | 1.78× | — | ||
| Q4 25 | 1.68× | 0.40× | ||
| Q3 25 | 1.78× | 0.46× | ||
| Q2 25 | 1.80× | 0.52× | ||
| Q1 25 | 1.64× | — | ||
| Q4 24 | 1.64× | 1.50× | ||
| Q3 24 | 1.80× | — | ||
| Q2 24 | 1.74× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $5.5M |
| Free Cash FlowOCF − Capex | — | $5.5M |
| FCF MarginFCF / Revenue | — | 16.1% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $5.5M | ||
| Q3 25 | $6.2B | $4.7M | ||
| Q2 25 | $4.4B | $-3.6M | ||
| Q1 25 | $4.8B | $-8.2M | ||
| Q4 24 | $5.8B | $-16.3M | ||
| Q3 24 | $-1.8B | $-18.1M | ||
| Q2 24 | $4.5B | $-19.1M |
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | $5.5M | ||
| Q3 25 | $5.6B | $4.2M | ||
| Q2 25 | $3.7B | $-3.8M | ||
| Q1 25 | $4.3B | $-8.3M | ||
| Q4 24 | $5.3B | — | ||
| Q3 24 | $-2.3B | — | ||
| Q2 24 | $4.0B | — |
| Q1 26 | — | — | ||
| Q4 25 | 21.4% | 16.1% | ||
| Q3 25 | 53.6% | 15.9% | ||
| Q2 25 | 36.3% | -14.7% | ||
| Q1 25 | 45.0% | -40.8% | ||
| Q4 24 | 53.1% | — | ||
| Q3 24 | -23.3% | — | ||
| Q2 24 | 40.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 0.1% | ||
| Q3 25 | 6.3% | 2.1% | ||
| Q2 25 | 6.0% | 0.8% | ||
| Q1 25 | 4.5% | 0.5% | ||
| Q4 24 | 5.0% | 0.0% | ||
| Q3 24 | 4.7% | 0.0% | ||
| Q2 24 | 5.8% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.25× | — | ||
| Q3 25 | 2.15× | — | ||
| Q2 25 | 1.51× | -0.05× | ||
| Q1 25 | 1.84× | — | ||
| Q4 24 | 2.66× | — | ||
| Q3 24 | -0.72× | — | ||
| Q2 24 | 1.50× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXP
| Discount revenue | $9.5M | 50% |
| Other | $8.9M | 47% |
| Deposits with banks and other | $512.0K | 3% |
ZVRA
| MIPLYFFA | $26.4M | 77% |
| Arimoclomol Purchase Agreement | $5.7M | 17% |
| Other | $2.0M | 6% |
